Show simple item record

dc.contributor.authorLe, Xiuning
dc.contributor.authorDeSai, Neelam V.
dc.contributor.authorMajid, Adnan
dc.contributor.authorKarp, Rebecca Sara
dc.contributor.authorHuberman, Mark S.
dc.contributor.authorRangachari, Deepa
dc.contributor.authorKent, Michael
dc.contributor.authorGangadharan, Sidhu
dc.contributor.authorFolch, Erik E
dc.contributor.authorVanderlaan, Paul A
dc.contributor.authorCosta, Daniel Botelho
dc.date.accessioned2018-05-25T15:53:34Z
dc.date.issued2015
dc.identifierQuick submit: 2017-07-13T12:51:19-0400
dc.identifier.citationLe, Xiuning, Neelam V. Desai, Adnan Majid, Rebecca S. Karp, Mark S. Huberman, Deepa Rangachari, Michael S. Kent, et al. 2015. “De Novo Pulmonary Small Cell Carcinomas and Large Cell Neuroendocrine Carcinomas Harboring EGFR Mutations: Lack of Response to EGFR Inhibitors.” Lung Cancer 88 (1) (April): 70–73. doi:10.1016/j.lungcan.2015.02.003.en_US
dc.identifier.issn0169-5002en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:37047104
dc.description.abstractIntroduction Epidermal growth factor receptor (EGFR) mutations are present in 10-20% of all non-small-cell lung cancers and predict for response to EGFR tyrosine kinase inhibitors (TKIs). However, the incidence of these mutations and their ability to predict response to TKIs in high-grade pulmonary neuroendocrine carcinomas [i.e. small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC)] is unknown. Methods The presence of EGFR mutations, clinicopathologic and anti-cancer therapy response data were retrospectively compiled and analyzed from a cohort of 608 patients-lung tumors to identify EGFR mutated high-grade pulmonary neuroendocrine carcinomas. We identified 126 EGFR-mutated (21.8% of 578 successful genotyped cases) lung cancers and only 2 (1.6%) were high-grade neuroendocrine carcinomas. Results Case one was of a 63 year-old white never smoker woman with extensive stage SCLC harboring EGFR-delL747_P753insS but without EGFR protein expression. After progression on carboplatin/etoposide, the patient was treated with erlotinib and developed progressive disease with a survival <3 months from start of erlotinib. Case two was of a 73 year-old Asian 30 pack-year smoker man with metastatic LCNEC harboring EGFR-delL747_P753insQS and also lacking EGFR protein expression. The patient received first line therapy with erlotinib and had progressive disease with a survival of 4 months. Conclusions The lack of response to EGFR TKIs in EGFR mutated de novo SCLC and LCNEC reported here may indicate that tumor differentiation affects tumor dependency on EGFR as a driver oncogene.en_US
dc.language.isoen_USen_US
dc.publisherElsevier BVen_US
dc.relation.isversionof10.1016/j.lungcan.2015.02.003en_US
dc.relation.hasversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355318/en_US
dash.licenseOAP
dc.titleDe novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitorsen_US
dc.typeJournal Articleen_US
dc.date.updated2017-07-13T16:51:25Z
dc.description.versionAccepted Manuscripten_US
dc.relation.journalLung Canceren_US
dash.depositing.authorFolch, Erik E
dc.date.available2015
dc.date.available2018-05-25T15:53:34Z
dc.identifier.doi10.1016/j.lungcan.2015.02.003*
dash.authorsorderedfalse
dash.contributor.affiliatedGangadharan, Sidhu
dash.contributor.affiliatedMajid, Adnan
dash.contributor.affiliatedKent, Michael
dash.contributor.affiliatedDeSai, Neelam
dash.contributor.affiliatedKarp, Rebecca
dash.contributor.affiliatedFolch, Erik
dash.contributor.affiliatedRangachari, Deepa
dash.contributor.affiliatedCosta, Daniel
dash.contributor.affiliatedVanderlaan, Paul


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record